Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

Français
Author : 
Auliac, JB ; Chouaid, C ; Greiller, L ; Monnet, I ; Le Caer, H ; Falchero, L & al
Newspaper edition : 
Lung Cancer - Année 2014 - Volume 85 - Page 415-9 - PMID 25082565